News | May 03, 2024
Novartis to acquire Mariana Oncology for upfront US$ 1 billion
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry
Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
New institute brings together Evonik’s most advanced biotech platform and a global network of evaluation labs
MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
Collaboration provides AstraZeneca with exclusive rights to Omniose’s proprietary bioconjugation platform to explore potential vaccines for a broad range of bacterial pathogens
BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
